Intest Res > v.24(2)

20 results

193 Tofacitinib in older patients with ulcerative colitis: balancing efficacy and safety
Yoon Suk Jung
KMSID: 1516096031   Intest Res. 2026;24(2):193-194.   Published online 2026 April 29    DOI: http://dx.doi.org/10.5217/ir.2026.00070
      
195 Can lifestyle restrictions prevent relapse in ulcerative colitis? A focus on quality of life
Jihye Park
KMSID: 1516096029   Intest Res. 2026;24(2):195-196.   Published online 2026 April 29    DOI: http://dx.doi.org/10.5217/ir.2026.00027
      
197 Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective
Shintaro Akiyama
KMSID: 1516096027   Intest Res. 2026;24(2):197-207.   Published online 2025 November 14    DOI: http://dx.doi.org/10.5217/ir.2025.00096
      
208 Recent updates on the endoscopic treatment of rectal neuroendocrine tumor
Sunghyeok Ryou, Kwangwoo Nam
KMSID: 1516096028   Intest Res. 2026;24(2):208-213.   Published online 2025 November 27    DOI: http://dx.doi.org/10.5217/ir.2025.00141
      
214 Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a post hoc analysis of safety and effectiveness in older (≥65 years) and younger (<65 years) patients
Katsuyoshi Matsuoka, Takayuki Yamamoto, Minoru Matsuura, Toshimitsu Fujii, Shoko Arai, Yutaka Endo, Keiko Sato, Hirotoshi Yuasa, Yasushi Mizuno, Yuki Kobayashi, Tadakazu Hisamatsu
KMSID: 1516096024   Intest Res. 2026;24(2):214-224.   Published online 2025 November 10    DOI: http://dx.doi.org/10.5217/ir.2025.00058
      
225 Lifestyle restrictions are associated with impaired quality of life but not reduction in relapse in ulcerative colitis
Hajime Yamazaki, Masakazu Nagahori, Tadakazu Hisamatsu, Taku Kobayashi, Teppei Omori, Jimmy K. Limdi, John T. McLaughlin, Shu-Chen Wei, Jovelle Fernandez, Shunichi Fukuhara, Katsuyoshi Matsuoka
KMSID: 1516096016   Intest Res. 2026;24(2):225-235.   Published online 2025 May 14    DOI: http://dx.doi.org/10.5217/ir.2024.00199
      
236 Clinical spectrum of acute severe ulcerative colitis in the biologic era: a prospective cohort study from India
Arshdeep Singh, Mayur Luthra, Arshia Bhardwaj, Ramit Mahajan, Riya Sharma, Dharmatma Singh, Devanshi Jain, Omesh Goyal, Varun Mehta, Kirandeep Kaur, Yogesh Kumar Gupta, Vandana Midha, Ajit Sood
KMSID: 1516096015   Intest Res. 2026;24(2):236-247.   Published online 2025 June 9    DOI: http://dx.doi.org/10.5217/ir.2024.00189
      
248 Anti-integrin αvβ6 autoantibody in patients with ulcerative colitis after proctocolectomy: a cross-sectional study in Japan
Tsuyoshi Yanagida, Yu Nishida, Yumie Kobayashi, Rieko Nakata, Shuhei Hosomi, Hirotsugu Maruyama, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuhiro Fujiwara
KMSID: 1516096014   Intest Res. 2026;24(2):248-254.   Published online 2025 April 29    DOI: http://dx.doi.org/10.5217/ir.2024.00170
      
255 Cross-ethnic evaluation of gut microbial signatures reveal increased colonization with oral pathobionts in the north Indian inflammatory bowel disease cohort
Arshdeep Singh, Garima Juyal, Ranko Gacesa, Mohan C. Joshi, Vandana Midha, B. K. Thelma, Rinse K Weersma, Ajit Sood
KMSID: 1516096018   Intest Res. 2026;24(2):255-269.   Published online 2025 July 14    DOI: http://dx.doi.org/10.5217/ir.2024.00216
      
270 Practices and perceptions of imaging assessment in inflammatory bowel disease: a nationwide survey of physicians in Korea by the KASID Guidelines Taskforce Team
Ji Eun Kim, Young Joo Yang, June Hwa Bae, Seung Yong Shin, Dong Hyun Kim, Seung Min Hong, Eun Mi Song, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Sung Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Myung Ha Kim, Won Moon, Sung-Ae Jung
KMSID: 1516096030   Intest Res. 2026;24(2):270-280.   Published online 2026 April 17    DOI: http://dx.doi.org/10.5217/ir.2026.00043
      
281 The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study
Taku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, Minoru Matsuura, Toshimitsu Fujii, Reiko Kunisaki, Tomoyoshi Shibuya, Ken Takeuchi, Sakiko Hiraoka, Hiroshi Yasuda, Kaoru Yokoyama, Noritaka Takatsu, Atsuo Maemoto, Toshiyuki Tahara, Keiichi Tominaga, Masaaki Shimada, Nobuaki Kuno, Mary Cavaliere, Kaori Ishiguro, Jovelle L Fernandez, Toshifumi Hibi
KMSID: 1516096012   Intest Res. 2026;24(2):281-292.   Published online 2025 June 4    DOI: http://dx.doi.org/10.5217/ir.2024.00126
      
293 Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study
Taku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, Toshimitsu Fujii, Reiko Kunisaki, Tomoyoshi Shibuya, Minoru Matsuura, Ken Takeuchi, Sakiko Hiraoka, Hiroshi Yasuda, Kaoru Yokoyama, Noritaka Takatsu, Atsuo Maemoto, Toshiyuki Tahara, Keiichi Tominaga, Masaaki Shimada, Nobuaki Kuno, Mary Cavaliere, Kaori Ishiguro, Jovelle L Fernandez, Toshifumi Hibi
KMSID: 1516096023   Intest Res. 2026;24(2):293-305.   Published online 2025 July 14    DOI: http://dx.doi.org/10.5217/ir.2025.00047
      
306 Efficacy and safety of carotegrast methyl in active ulcerative colitis: a real-world prospective cohort study
Takahiro Shimoyama, Takayuki Yamamoto, Haruka Miyao, Saki Aota, Shoichi Morita, Ryohei Sakaguchi
KMSID: 1516096022   Intest Res. 2026;24(2):306-315.   Published online 2025 July 14    DOI: http://dx.doi.org/10.5217/ir.2025.00046
      
316 Real-world effectiveness and safety of carotegrast methyl in patients with ulcerative colitis: a multicenter retrospective cohort study
Ryoji Koshiba, Kazuki Kakimoto, Takuya Inoue, Makoto Sanomura, Mitsuyuki Murano, Hiroaki Ito, Yoshihiko Nakanishi, Ken Kawakami, Noboru Mizuta, Keijiro Numa, Naohiko Kinoshita, Kei Nakazawa, Azusa Hara, Yuki Hirata, Naokuni Sakiyama, Shoko Arimitsu, Takako Miyazaki, Shiro Nakamura, Hiroki Nishikawa
KMSID: 1516096025   Intest Res. 2026;24(2):316-328.   Published online 2025 August 12    DOI: http://dx.doi.org/10.5217/ir.2025.00066
      
329 Ulcerative colitis disease severity affects the speed of symptom relief under filgotinib treatment: a post hoc analysis of the phase 2b/3 SELECTION study
Masayuki Saruta, Silvio Danese, Yoshie Takatori, Toshihiko Kaise, Christine Rudolph, Marc Ferrante, Toshifumi Hibi
KMSID: 1516096013   Intest Res. 2026;24(2):329-340.   Published online 2025 June 30    DOI: http://dx.doi.org/10.5217/ir.2024.00169
      
341 Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study
Antonio Tursi, Giammarco Mocci, Francesco Costa, Linda Ceccarelli, Edoardo Savarino, Caterina De Barba, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Manuela Marzo, Franco Scaldaferri, Daniele Napolitano, Daniela Pugliese, Antonietta Gerarda Gravina, Raffaele Pellegrino, Rocco Spagnuolo, Francesco Luzza, Antonio Cuomo, Laura Donnarumma, Giovanni Maconi, Giovanni Cataletti, Lorenzo Bertani, Giorgia Bodini, Andrea Pasta, Simona Piergallini, Mariaelena Serio, Antonella Scarcelli, Pietro Capone, Fabio Cortellini, Stefano Rodino, Ladislava Sebkova, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Federica Gaiani, Stefano Kayali, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Antonio Ferronato, Davide Giuseppe Ribaldone, Giovanni Aragona, Patrizia Perazzo, Giacomo Forti, Michela Di Fonzo, Federico Iacopini, Roberta Pica, Claudio Cassieri, Francesca Maria Onidi, Paolo Usai Satta, Walter Elisei, Marcello Picchio, Alfredo Papa
KMSID: 1516096026   Intest Res. 2026;24(2):341-351.   Published online 2025 September 29    DOI: http://dx.doi.org/10.5217/ir.2025.00067
      
352 Efficacy and safety of etrasimod in Japanese patients with ulcerative colitis: results from a phase 2 dose-ranging study
Ken Takeuchi, Hiroshi Nakase, Tadakazu Hisamatsu, Katsuyoshi Matsuoka, Shoko Arai, Hirotoshi Yuasa, Motoki Oe, Ryosuke Ono, Michael Keating, Guibao Gu, Krisztina Lazin, Aoibhinn McDonnell, Koki Fukuta, Toshifumi Hibi
KMSID: 1516096017   Intest Res. 2026;24(2):352-365.   Published online 2025 April 25    DOI: http://dx.doi.org/10.5217/ir.2024.00213
      
366 Treatment patterns and outcomes in patients with steroid-dependent ulcerative colitis in Japan: a claims database study
Masayuki Saruta, Takumi Sugiyama, Takumi Tajima, Chisa Nagakura, Yan Zhong, Toshihiko Kaise
KMSID: 1516096021   Intest Res. 2026;24(2):366-375.   Published online 2025 November 13    DOI: http://dx.doi.org/10.5217/ir.2025.00032
      
376 Antinuclear antibodies seroconversion and endoscopic response to infliximab in biologic-naive Crohn’s disease: a Chinese single-center, retrospective study
Jinlu Tong, Xitao Xu, Yuan Cao, Mingming Zhu, Juntao Lu, Yuqi Qiao, Zhanghan Dai, Tianrong Wang, Ying Sun, Zhijun Cao, Shen Jun
KMSID: 1516096020   Intest Res. 2026;24(2):376-383.   Published online 2025 November 14    DOI: http://dx.doi.org/10.5217/ir.2025.00018
      
384 Neo-left colon volvulus or metachronous descending colon volvulus following sigmoidectomy for sigmoid volvulus
Sabri Selcuk Atamanalp
KMSID: 1516096019   Intest Res. 2026;24(2):384-386.   Published online 2025 July 23    DOI: http://dx.doi.org/10.5217/ir.2025.00015
      
Articles from Intestinal Research are provided here courtesy of Korean Association for the Study of Intestinal Diseases